Zobrazeno 1 - 10
of 257
pro vyhledávání: '"Krishna R. Kalari"'
Autor:
Roberto A. Leon-Ferre, Jodi M. Carter, David Zahrieh, Jason P. Sinnwell, Roberto Salgado, Vera J. Suman, David W. Hillman, Judy C. Boughey, Krishna R. Kalari, Fergus J. Couch, James N. Ingle, Maschenka Balkenhol, Francesco Ciompi, Jeroen van der Laak, Matthew P. Goetz
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Operable triple-negative breast cancer (TNBC) has a higher risk of recurrence and death compared to other subtypes. Tumor size and nodal status are the primary clinical factors used to guide systemic treatment, while biomarkers of proliferat
Externí odkaz:
https://doaj.org/article/76fed00f45b74d1e9623e4f305759050
Autor:
Swaathi Jayaraman, Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha (ERα) binding at nanomolar concentrations. Phase I/II clinical trials identified clinical activity of Z-endoxifen (ENDX), in endocrine-
Externí odkaz:
https://doaj.org/article/809fda6ff0ea4cad83dc611d55814884
Autor:
August J. John, Emily T. Ghose, Huanyao Gao, Meagan Luck, Dabin Jeong, Krishna R. Kalari, Liewei Wang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Cancer is typically treated with combinatorial therapy, and such combinations may be synergistic. However, discovery of these combinations has proven difficult as brute force combinatorial screening approaches are both logistically complex and resour
Externí odkaz:
https://doaj.org/article/a11a1ef86c9b4eb8bfce94aebe41231e
Autor:
Xiaojia Tang, Kevin J. Thompson, Krishna R. Kalari, Jason P. Sinnwell, Vera J. Suman, Peter T. Vedell, Sarah A. McLaughlin, Donald W. Northfelt, Alvaro Moreno Aspitia, Richard J. Gray, Jodi M. Carter, Richard Weinshilboum, Liewei Wang, Judy C. Boughey, Matthew P. Goetz
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-18 (2023)
Abstract Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Patients with TNBC are primarily treated with neoadjuvant chemotherapy (NAC). The response to NAC is prognostic, with reductions in overall surviva
Externí odkaz:
https://doaj.org/article/3af3f74d177a4754a631cf8c8eef5d57
Autor:
Jodi M. Carter, Saranya Chumsri, Douglas A. Hinerfeld, Yaohua Ma, Xue Wang, David Zahrieh, David W. Hillman, Kathleen S. Tenner, Jennifer M. Kachergus, Heather Ann Brauer, Sarah E. Warren, David Henderson, Ji Shi, Yi Liu, Heikki Joensuu, Henrik Lindman, Roberto A. Leon-Ferre, Judy C. Boughey, Minetta C. Liu, James N. Ingle, Krishna R. Kalari, Fergus J. Couch, Keith L. Knutson, Matthew P. Goetz, Edith A. Perez, E. Aubrey Thompson
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract The utility of spatial immunobiomarker quantitation in prognostication and therapeutic prediction is actively being investigated in triple-negative breast cancer (TNBC). Here, with high-plex quantitative digital spatial profiling, we map and
Externí odkaz:
https://doaj.org/article/d5560e60b96445c4af2242dfe42eae7f
Publikováno v:
npj Systems Biology and Applications, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Critical functions of the blood–brain barrier (BBB), including cerebral blood flow, energy metabolism, and immunomodulation, are regulated by insulin signaling pathways. Therefore, endothelial insulin resistance could lead to BBB dysfuncti
Externí odkaz:
https://doaj.org/article/d712fd81446447ada84e352ce0d53510
Autor:
Kirsten G. M. Aspros, Jodi M. Carter, Tanya L. Hoskin, Vera J. Suman, Malayannan Subramaniam, Michael J. Emch, Zhenqing Ye, Zhifu Sun, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Esther P. B. Rodman, Xiyin Wang, Adam W. Nelson, Igor Chernukhin, Feda H. Hamdan, Elizabeth S. Bruinsma, Jason S. Carroll, Martin E. Fernandez-Zapico, Steven A. Johnsen, Krishna R. Kalari, Haojie Huang, Roberto A. Leon-Ferre, Fergus J. Couch, James N. Ingle, Matthew P. Goetz, John R. Hawse
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-15 (2022)
Abstract Triple Negative Breast Cancer (TNBC) accounts for 15–20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of breast cancer mortalities. Thus, there is an urgent need to identify novel biomarkers and t
Externí odkaz:
https://doaj.org/article/cb14a3f8cc2f47efa372c800d589e31a
Autor:
Yongxian Zhuang, Jordan M. Grainger, Peter T. Vedell, Jia Yu, Ann M. Moyer, Huanyao Gao, Xiao-Yang Fan, Sisi Qin, Duan Liu, Krishna R. Kalari, Matthew P. Goetz, Judy C. Boughey, Richard M. Weinshilboum, Liewei Wang
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-12 (2021)
Abstract The application of patient-derived xenografts (PDX) in drug screening and testing is a costly and time-consuming endeavor. While cell lines permit extensive mechanistic studies, many human breast cancer cell lines lack patient characteristic
Externí odkaz:
https://doaj.org/article/d0faaa823e1d474ca427db78a9f24251
Autor:
Lingxin Zhang, Vivekananda Sarangi, Irene Moon, Jia Yu, Duan Liu, Sandhya Devarajan, Joel M. Reid, Krishna R. Kalari, Liewei Wang, Richard Weinshilboum
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 4, Pp 727-742 (2020)
Single nucleotide variants in the open reading frames (ORFs) of pharmacogenes are important causes of interindividual variability in drug response. The functional characterization of variants of unknown significance within ORFs remains a major challe
Externí odkaz:
https://doaj.org/article/1144fdfe27ac414da66d29418b5a2e86
Autor:
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-12 (2020)
Abstract Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole
Externí odkaz:
https://doaj.org/article/1f0ba8cf46c9435685e14beccf269d8f